Researchers test canine non-Hodgkin's lymphoma vaccine

10/19/2011 | ScienceDaily

Researchers from the University of Pennsylvania's schools of Medicine and Veterinary Medicine developed a vaccine for dogs with spontaneous non-Hodgkin's lymphoma that increased survival time. The vaccine uses the patient's own RNA and easy-to-isolate B-cells, as opposed to other attempts that used dendritic cells, which are cumbersome to produce. When relapse occurred after standard chemotherapy, 40% of the vaccinated dogs had long-term survival after a second round of chemotherapy, versus only 7% of non-vaccinated dogs.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA